Where does Tango Therapeutics's income statement data come from?

Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net interest income	$6.19M+10.0%	$5.63M-2.3%	$5.76M-11.0%	$6.48M-11.4%	$7.31M-7.4%
Total revenue	$56.99M-8.6%	$62.38M-6.2%	$66.5M+174%	$24.3M-40.7%	$40.99M-2.6%
Research and development	$129.26M-2.2%	$132.17M-1.4%	$134M-1.8%	$136.45M-4.1%	$142.3M-1.1%
Other operating expenses	$174.52M+0.5%	$173.67M-1.8%	$176.84M-2.6%	$181.58M-2.8%	$186.86M-0.4%
Total operating expenses	$174.52M+0.5%	$173.67M-1.8%	$176.84M-2.6%	$181.58M-2.8%	$186.86M-0.4%
Other income (expense), net	$10.27M+5.9%	$9.7M-2.3%	$9.93M-16.5%	$11.89M-13.9%	$13.81M-10.9%
Net income	-$107.23M-5.5%	-$101.59M-1.1%	-$100.52M+30.9%	-$145.57M-10.1%	-$132.26M-1.5%
Net margin	-188.2%-25.3pp	-162.9%-11.7pp	-151.1%+448pp	-599.1%-276pp	-322.7%-12.9pp
Basic earnings per share	-$0.83+4.6%	-$0.87+4.4%	-$0.91+31.1%	-$1.32-9.1%	-$1.21-0.8%
Weighted-average shares, basic	481.2M+7.4%	448M+1.6%	441M+0.6%	438.6M+0.5%	436.3M+0.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$107.54M-5.7%	-$101.71M-0.6%	-$101.14M+30.3%	-$145.14M-10.1%	-$131.81M-1.3%
Interest Income (Expense), Operating	$6.19M+10.0%	$5.63M-2.3%	$5.76M-11.0%	$6.48M-11.4%	$7.31M-7.4%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$302.34M+35.9%	$222.5M+5,336%	$4.09M+3.5%	$3.95M-15.6%	$4.68M-90.2%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$61.83M-51.3%	-$40.87M-128%	$146.91M+11.3%	$132.01M+3.2%	$127.93M+48.5%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$141.55M-1.9%	-$138.89M+4.8%	-$145.82M+1.6%	-$148.25M-9.5%	-$135.34M-2.9%
Other income, net (Note 6)	$4.07M+0.1%	$4.07M-2.3%	$4.17M-23.1%	$5.42M-16.7%	$6.5M-14.6%
Payments Of Stock Issuance Costs	$564K+1,467%	$36K—	——	——	——
EBITDA	-$115.41M-5.9%	-$109.01M-1.0%	-$107.91M+30.3%	-$154.8M-8.0%	-$143.37M-0.2%
EBITDA margin	-202.5%-27.8pp	-174.7%-12.5pp	-162.3%+475pp	-637.1%-287pp	-349.8%-9.6pp
EBIT	-$117.53M-5.6%	-$111.29M-0.9%	-$110.34M+29.9%	-$157.29M-7.8%	-$145.87M-0.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Tango Therapeutics's income statement data come from?: Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.